Opioid agonist/antagonist combinations
US8932630B1 · kind B1 · utility
13Cited by
209References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 18, 2014 |
| Grant date | Jan 13, 2015 |
| Priority date | — |
| Expiry date | Sep 18, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/1694
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.